CARsgen Therapeutics Holdings Limited (HKG:2171)

Revenue by Product

Financials in millions HKD. Fiscal year is January - December.

Year Ending	Dec 31, 2024	Dec 31, 2021
CAR T-cell Therapies	42.75M	Log In
CAR T-cell Therapies Growth	37.40%	Log In

Revenue by Geography

Financials in millions HKD. Fiscal year is January - December.

Year Ending	Dec 31, 2024	Dec 31, 2021
China	42.75M	Log In
China and United States	-	Log In